{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T18:18:46Z","timestamp":1774462726614,"version":"3.50.1"},"reference-count":72,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2019 432 110570GB-I00."],"award-info":[{"award-number":["PID2019 432 110570GB-I00."]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Herpes simplex viruses (HSVs) are neurotropic viruses with broad host range whose infections cause considerable health problems in both animals and humans. In fact, 67% of the global population under the age of 50 are infected with HSV-1 and 13% have clinically recurrent HSV-2 infections. The most prescribed antiherpetics are nucleoside analogues such as acyclovir, but the emergence of mutants resistant to these drugs and the lack of available vaccines against human HSVs has led to an imminent need for new antivirals. Valproic acid (VPA) is a branched short-chain fatty acid clinically used as a broad-spectrum antiepileptic drug in the treatment of neurological disorders, which has shown promising antiviral activity against some herpesviruses. Moreover, its amidic derivatives valpromide and valnoctamide also share this antiherpetic activity. This review summarizes the current research on the use of VPA and its amidic derivatives as alternatives to traditional antiherpetics in the fight against HSV infections.<\/jats:p>","DOI":"10.3390\/v12121356","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T09:04:15Z","timestamp":1606381455000},"page":"1356","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Valproic Acid and Its Amidic Derivatives as New Antivirals against Alphaherpesviruses"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0600-4152","authenticated-orcid":false,"given":"Sabina","family":"Andreu","sequence":"first","affiliation":[{"name":"Departamento de Biolog\u00eda Molecular, Universidad Aut\u00f3noma de Madrid, Cantoblanco, 28049 Madrid, Spain"},{"name":"Centro de Biolog\u00eda Molecular Severo Ochoa, Spanish National Research Council\u2014Universidad Aut\u00f3noma de Madrid (CSIC-UAM), Cantoblanco, 28049 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"Ripa","sequence":"additional","affiliation":[{"name":"Departamento de Biolog\u00eda Molecular, Universidad Aut\u00f3noma de Madrid, Cantoblanco, 28049 Madrid, Spain"},{"name":"Centro de Biolog\u00eda Molecular Severo Ochoa, Spanish National Research Council\u2014Universidad Aut\u00f3noma de Madrid (CSIC-UAM), Cantoblanco, 28049 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4415-6483","authenticated-orcid":false,"given":"Raquel","family":"Bello-Morales","sequence":"additional","affiliation":[{"name":"Departamento de Biolog\u00eda Molecular, Universidad Aut\u00f3noma de Madrid, Cantoblanco, 28049 Madrid, Spain"},{"name":"Centro de Biolog\u00eda Molecular Severo Ochoa, Spanish National Research Council\u2014Universidad Aut\u00f3noma de Madrid (CSIC-UAM), Cantoblanco, 28049 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-5956","authenticated-orcid":false,"given":"Jos\u00e9 Antonio","family":"L\u00f3pez-Guerrero","sequence":"additional","affiliation":[{"name":"Departamento de Biolog\u00eda Molecular, Universidad Aut\u00f3noma de Madrid, Cantoblanco, 28049 Madrid, Spain"},{"name":"Centro de Biolog\u00eda Molecular Severo Ochoa, Spanish National Research Council\u2014Universidad Aut\u00f3noma de Madrid (CSIC-UAM), Cantoblanco, 28049 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00705-008-0278-4","article-title":"The order Herpesvirales","volume":"154","author":"Davison","year":"2009","journal-title":"Arch. Virol."},{"key":"ref_2","first-page":"1635","article-title":"Human herpes simplex virus: Life cycle and development of inhibitors","volume":"79","author":"Kukhanova","year":"2014","journal-title":"Biochemistry"},{"key":"ref_3","unstructured":"Carrasco, L., and Almendral, J.M. (2006). Virus Pat\u00f3genos, Editorial H\u00e9lice, Fundaci\u00f3n BBVA."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Smith, T.T., and Whitley, R.J. (2017). Herpesviruses. Infectious Diseases, Elsevier.","DOI":"10.1016\/B978-0-7020-6285-8.00166-0"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/jac\/39.2.119","article-title":"New therapeutic approaches to the alphaherpesvirus infections","volume":"39","author":"Cassady","year":"1997","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3851\/IMP3018","article-title":"Herpes simplex virus type-1: Replication, latency, reactivation and its antiviral targets","volume":"21","author":"Bloom","year":"2016","journal-title":"Antivir. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/B978-0-444-53488-0.00011-0","article-title":"Herpes simplex virus","volume":"Volume 123","author":"Widener","year":"2014","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_8","first-page":"928","article-title":"Genital Herpes: A Review","volume":"93","author":"Groves","year":"2016","journal-title":"Am. Fam. Physician."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11916-017-0635-7","article-title":"Recurrent Meningitis","volume":"21","author":"Rosenberg","year":"2017","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kennedy, P.G.E., and Gershon, A.A. (2018). Clinical features of varicella-zoster virus infection. Viruses, 10.","DOI":"10.3390\/v10110609"},{"key":"ref_11","first-page":"531","article-title":"Molecular biology of animal herpesviruses","volume":"Volume 12","author":"Mettenleiter","year":"2008","journal-title":"Animal viruses: Molecular Biology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/01652176.2013.799301","article-title":"Bovine herpesvirus-1 (BHV-1) a re-emerging concern in livestock: A revisit to its biology, epidemiology, diagnosis, and prophylaxis","volume":"33","author":"Biswas","year":"2013","journal-title":"Vet. Q."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1017\/S0950268817001546","article-title":"A systematic review of varicella seroprevalence in European countries before universal childhood immunization: Deriving incidence from seroprevalence data","volume":"145","author":"Bollaerts","year":"2017","journal-title":"Epidemiol. Infect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ijos.2016.3","article-title":"New strategies against drug resistance to herpes simplex virus","volume":"8","author":"Jiang","year":"2016","journal-title":"Int. J. Oral Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0190-9622(88)70022-5","article-title":"History, pharmacokinetics, and pharmacology of acyclovir","volume":"18","author":"King","year":"1988","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-981-10-7230-7_6","article-title":"Antiviral drugs against alphaherpesvirus","volume":"Volume 1045","author":"Kawaguchi","year":"2018","journal-title":"Human Herpesviruses. Advances in Experimental Medicine and Biology"},{"key":"ref_17","first-page":"708","article-title":"Valaciclovir","volume":"129","year":"2002","journal-title":"Ann. Dermatol. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.podrm.2017.12.001","article-title":"Ganciclovir","volume":"Volume 43","author":"Ajarim","year":"2018","journal-title":"Profiles of Drug Substances, Excipients and Related Methodology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1016\/j.vaccine.2015.12.076","article-title":"Status of vaccine research and development of vaccines for herpes simplex virus","volume":"34","author":"Johnston","year":"2016","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Levin, M.J., Bacon, T.H., and Leary, J.J. (2004). Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin. Infect. Dis., 39.","DOI":"10.1086\/422364"},{"key":"ref_21","unstructured":"Garikapati, S., and Nguyen, M. (2020). Foscarnet, StatPearls Publishing."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/QCO.0000000000000288","article-title":"Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: Diagnosis and management","volume":"29","author":"Piret","year":"2016","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.tvjl.2015.06.010","article-title":"Antiviral agents against equid alphaherpesviruses: Current status and perspectives","volume":"207","author":"Vissani","year":"2016","journal-title":"Vet. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-405880-4.00001-9","article-title":"Antiviral agents for herpes simplex virus","volume":"Volume 67","author":"Field","year":"2013","journal-title":"Advances in Pharmacology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/QCO.0000000000000211","article-title":"Herpes simplex virus and varicella zoster virus: Recent advances in therapy","volume":"28","author":"De","year":"2015","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Gil, M., Gonz\u00e1lez-Gonz\u00e1lez, R., V\u00e1zquez-Calvo, A., \u00c1lvarez-Guti\u00e9rrez, A., Mart\u00edn-Acebes, M.A., Praena, B., Bello-Morales, R., Saiz, J.C., L\u00f3pez-Guerrero, J.A., and Tabar\u00e9s, E. (2019). Clinical Infections by Herpesviruses in Patients Treated with Valproic Acid: A Nested Case-Control Study in the Spanish Primary Care Database, BIFAP. J. Clin. Med., 8.","DOI":"10.3390\/jcm8091442"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/jhg.2017.91","article-title":"The pharmacogenomics of valproic acid","volume":"62","author":"Zhu","year":"2017","journal-title":"J. Hum. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","article-title":"Adverse drug reactions induced by valproic acid","volume":"46","author":"Nanau","year":"2013","journal-title":"Clin. Biochem."},{"key":"ref_29","first-page":"CD010611","article-title":"Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults","volume":"24","author":"Linde","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: A 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","article-title":"Valproic acid after five decades of use in epilepsy: Time to reconsider the indications of a time-honoured drug","volume":"15","author":"Tomson","year":"2016","journal-title":"Lancet Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Diederich, M., Chateauvieux, S., Morceau, F., and Dicato, M. (2010). Molecular and therapeutic potential and toxicity of valproic acid. J. Biomed. Biotechnol.","DOI":"10.1155\/2010\/479364"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0361-9230(94)90202-X","article-title":"Valproic acid suppresses the synaptic response mediated by the NMDA receptors in rat amygdalar slices","volume":"33","author":"Gean","year":"1994","journal-title":"Brain Res. Bull."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"26549","DOI":"10.1073\/pnas.1909696116","article-title":"Valproic acid interactions with the NavMs voltage-gated sodium channel","volume":"116","author":"Zanatta","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.mp.4001087","article-title":"Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity","volume":"7","author":"Farber","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pbb.2018.02.001","article-title":"Neuroprotective effects of valproic acid on brain ischemia are related to its HDAC and GSK3 inhibitions","volume":"167","author":"Silva","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ghodke-Puranik, Y., Thorn, C.F., Lamba, J.K., Leeder, J.S., Song, W., Birnbaum, A.K., Altman, R.B., and Klein, T.E. (2013). Valproic acid pathway: Pharmacokinetics and pharmacodynamics. Pharm. Genom.","DOI":"10.1097\/FPC.0b013e32835ea0b2"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-981-10-7230-7_4","article-title":"Oncolytic virotherapy by HSV","volume":"Volume 1045","author":"Watanabe","year":"2018","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1128\/JVI.01717-10","article-title":"Inhibition of Enveloped Virus Infection of Cultured Cells by Valproic Acid","volume":"85","author":"Saiz","year":"2011","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.virusres.2016.01.009","article-title":"Inhibition of herpes virus infection in oligodendrocyte cultured cells by valproic acid","volume":"214","author":"Crespillo","year":"2016","journal-title":"Virus Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Bello-Morales, R., Andreu, S., and L\u00f3pez-Guerrero, J.A. (2020). The role of herpes simplex virus type 1 infection in demyelination of the central nervous system. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21145026"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/13550280590924179","article-title":"High susceptibility of a human oligodendroglial cell line to herpes simplex type 1 infection","volume":"11","author":"Fedetz","year":"2005","journal-title":"J. Neurovirol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4103\/1673-5374.226380","article-title":"Contributions of neurotropic human herpesviruses herpes simplex virus 1 and human herpesvirus 6 to neurodegenerative disease pathology","volume":"13","author":"Hogestyn","year":"2018","journal-title":"Neural Regen. Res."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bello-Morales, R., Crespillo, A.J., Garc\u00eda, B., Dorado, L.\u00c1., Mart\u00edn, B., Tabar\u00e9s, E., Krummenacher, C., De Castro, F., and L\u00f3pez-Guerrero, J.A. (2014). The effect of cellular differentiation on HSV-1 infection of oligodendrocytic cells. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0089141"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.antiviral.2013.05.012","article-title":"Inhibition of multiplication of the prototypic arenavirus LCMV by valproic acid","volume":"99","author":"Ngo","year":"2013","journal-title":"Antiviral Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1552-6909.1986.tb01376.x","article-title":"Teratogenic Potential of Valproic Acid","volume":"15","author":"Hanold","year":"1986","journal-title":"J. Obstet. Gynecol. Neonatal Nurs."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.reprotox.2009.02.014","article-title":"Valproic acid in pregnancy: How much are we endangering the embryo and fetus?","volume":"28","author":"Ornoy","year":"2009","journal-title":"Reprod. Toxicol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00019052-200304000-00014","article-title":"New CNS-active drugs which are second-generation valproic acid: Can they lead to the development of a magic bullet?","volume":"16","author":"Isoherranen","year":"2003","journal-title":"Curr. Opin. Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2019.05.006","article-title":"Amidic derivatives of valproic acid, valpromide and valnoctamide, inhibit HSV-1 infection in oligodendrocytes","volume":"168","author":"Praena","year":"2019","journal-title":"Antiviral Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/sj.bjp.0706310","article-title":"Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain","volume":"146","author":"Winkler","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Kudin, A.P., Mawasi, H., Eisenkraft, A., Elger, C.E., Bialer, M., and Kunz, W.S. (2017). Mitochondrial liver toxicity of valproic acid and its acid derivatives is related to inhibition of \u03b1-lipoamide dehydrogenase. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18091912"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.neuropharm.2010.03.004","article-title":"Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid","volume":"58","author":"Kaufmann","year":"2010","journal-title":"Neuropharmacology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.addr.2011.11.006","article-title":"Chemical properties of antiepileptic drugs (AEDs)","volume":"64","author":"Bialer","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nurt.2006.11.007","article-title":"Valproic Acid: Second Generation","volume":"4","author":"Bialer","year":"2007","journal-title":"Neurotherapeutics"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF00315032","article-title":"Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects","volume":"38","author":"Bialer","year":"1990","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_56","unstructured":"(2020, October 28). European Medicines Agency (EMA) Valproate and Related Substances. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/valproate-related-substances-0#overview-section."},{"key":"ref_57","unstructured":"(2020, October 28). Vademecum 2020 Valpromida 2020. Available online: https:\/\/www.vademecum.es\/principios-activos-valpromida-N03AG02."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2165\/00003088-199120020-00003","article-title":"Clinical Pharmacology of Valpromide","volume":"20","author":"Bialer","year":"1991","journal-title":"Clin. Pharmacokinet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/bdrb.10057","article-title":"Amidic Modification of Valproic Acid Reduces Skeletal Teratogenicity in Mice","volume":"71","author":"Okada","year":"2004","journal-title":"Birth Defects Res. Part B Dev. Reprod. Toxicol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(99)00037-1","article-title":"Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs","volume":"62","author":"Bialer","year":"1999","journal-title":"J. Control. Release"},{"key":"ref_61","first-page":"2","article-title":"Can we develop improved derivatives of valproic acid? Pharm","volume":"16","author":"Bialer","year":"1994","journal-title":"World Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1023\/A:1025069519218","article-title":"Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy","volume":"20","author":"Isoherranen","year":"2003","journal-title":"Pharm. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.psychres.2017.04.048","article-title":"Valnoctamide, which reduces rat brain arachidonic acid turnover, is a potential non-teratogenic valproate substitute to treat bipolar disorder","volume":"254","author":"Modi","year":"2017","journal-title":"Psychiatry Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.yebeh.2015.04.012","article-title":"The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus","volume":"49","author":"Mawasi","year":"2015","journal-title":"Epilepsy Behav."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1523\/JNEUROSCI.0970-17.2017","article-title":"Valnoctamide inhibits cytomegalovirus infection in developing brain and attenuates neurobehavioral dysfunctions and brain abnormalities","volume":"37","author":"Ornaghi","year":"2017","journal-title":"J. Neurosci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1399-5618.2010.00828.x","article-title":"Valnoctamide as a valproate substitute with low teratogenic potential in mania: A double-blind, controlled, add-on clinical trial","volume":"12","author":"Bersudsky","year":"2010","journal-title":"Bipolar Disord."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/epi.13634","article-title":"Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII)","volume":"58","author":"Bialer","year":"2017","journal-title":"Epilepsia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/bdr2.1406","article-title":"Teratogenicity of valproic acid and its constitutional isomer, amide derivative valnoctamide in mice","volume":"111","author":"Lin","year":"2019","journal-title":"Birth Defects Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.virol.2016.09.012","article-title":"Mood stabilizers inhibit cytomegalovirus infection","volume":"499","author":"Ornaghi","year":"2016","journal-title":"Virology"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Gorres, K.L., Daigle, D., Mohanram, S., McInerney, G.E., Lyons, D.E., and Miller, G. (2016). Valpromide inhibits Lytic cycle reactivation of epstein-Barr virus. MBio, 7.","DOI":"10.1128\/mBio.00113-16"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Anderson, A.G., Gaffy, C.B., Weseli, J.R., and Gorres, K.L. (2019). Inhibition of epstein-barr virus lytic reactivation by the atypical antipsychotic drug clozapine. Viruses, 11.","DOI":"10.3390\/v11050450"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Singh, S., and Singh, K. (2020). Valproic Acid in Prevention and Treatment of COVID-19. Authorea Prepr.","DOI":"10.22541\/au.159000338.83671779"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/12\/1356\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:37:54Z","timestamp":1760179074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/12\/1356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,26]]},"references-count":72,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["v12121356"],"URL":"https:\/\/doi.org\/10.3390\/v12121356","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,26]]}}}